MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-10-2026
Exagen Interest Expense 2011-2026 | XGN
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Exagen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 2.34 M | 2.45 M | 2.62 M | 2.56 M | 3.49 M | 2.87 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.49 M | 2.34 M | 2.72 M |
Quarterly Interest Expense Exagen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 549 K | - | 557 K | 574 K | 638 K | - | 618 K | 606 K | 598 K | - | 678 K | 663 K | 645 K | - | 647 K | 635 K | 631 K | - | 909 K | 910 K | 901 K | - | 704 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 910 K | 549 K | 674 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M |  USA |
 |
Agilent Technologies
A
|
81 M | $ 115.55 | 3.81 % | $ 35.1 B | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 20.81 | 0.05 % | $ 1.11 B | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 1.55 | 1.31 % | $ 2.06 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 24.49 | 1.03 % | $ 680 M | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 15.19 | 2.64 % | $ 459 M | USA |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 118.33 | 1.86 % | $ 9.76 B |  Irlanda |
 |
Illumina
ILMN
|
-292 M | $ 126.74 | 5.29 % | $ 20.2 B | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 166.97 | 1.91 % | $ 8.28 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 84.62 | 4.25 % | $ 5.71 B | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 418.66 | 1.23 % | $ 12.1 B | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 87.08 | 4.4 % | $ 10.9 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 26.34 | 2.95 % | $ 20 B |  Niderland |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.75 | 1.5 % | $ 440 M | USA |
 |
Interpace Biosciences
IDXG
|
-252 K | $ 1.98 | -0.5 % | $ 8.76 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 9.26 | 3.35 % | $ 1.19 B | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | Niderland |
 |
Biomerica
BMRA
|
367 | $ 2.18 | 0.93 % | $ 5.01 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 256.8 | -0.13 % | $ 21.4 B | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 16.46 | -0.48 % | $ 368 M | USA |
 |
Celcuity
CELC
|
2.11 M | $ 121.35 | 1.97 % | $ 5.67 B | USA |
 |
Natera
NTRA
|
9.32 M | $ 206.16 | 5.86 % | $ 20.3 B | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 9.4 | 4.33 % | $ 2.04 B | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 194.2 | 2.58 % | $ 21.6 B | USA |
 |
OpGen
OPGN
|
7.56 K | - | -16.95 % | $ 1.54 M | USA |
 |
Organovo Holdings
ONVO
|
6 K | - | -2.3 % | $ 19.4 M | USA |
 |
PerkinElmer
PKI
|
-3.36 M | - | -0.91 % | $ 14.7 B | USA |
 |
Precipio
PRPO
|
839 K | $ 30.9 | 3.21 % | $ 49.6 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 17.0 | 4.68 % | $ 179 M | China |
 |
Personalis
PSNL
|
24 K | $ 5.52 | 9.52 % | $ 327 M | USA |